81 related articles for article (PubMed ID: 21801127)
1. Bringing prognostic scores for chronic myeloid leukemia patients up to date.
Breccia M; Alimena G
Expert Rev Hematol; 2011 Aug; 4(4):373-5. PubMed ID: 21801127
[No Abstract] [Full Text] [Related]
2. Prognostic variables in patients with chronic myeloid leukemia treated with imatinib.
Gambacorti-Passerini C
Haematologica; 2006 Feb; 91(2):145a. PubMed ID: 16461289
[No Abstract] [Full Text] [Related]
3. Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia.
Ames PR; Aye WW; Beatty C; O'Reilly D
J Rheumatol; 2008 Aug; 35(8):1682. PubMed ID: 18671330
[No Abstract] [Full Text] [Related]
4. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
5. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
[No Abstract] [Full Text] [Related]
6. Chronic myelogenous leukemia therapy beyond imatinib.
Deininger M
Clin Adv Hematol Oncol; 2010 Mar; 8(3):178-80. PubMed ID: 20400933
[No Abstract] [Full Text] [Related]
7. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
[No Abstract] [Full Text] [Related]
8. Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations?
Jiménez-Velasco A; Barrios M; Alcalá M; Heiniger AI
J Clin Oncol; 2010 Jun; 28(18):e310; author reply e311. PubMed ID: 20479423
[No Abstract] [Full Text] [Related]
9. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
10. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
Rodrigues MS; Sattler M
J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
[No Abstract] [Full Text] [Related]
11. Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.
Racil Z; Klamova H; Voglova J; Faber E; Razga F; Zackova D; Buresova L; Cetkovsky P; Mayer J
Am J Hematol; 2010 May; 85(5):386-9. PubMed ID: 20425803
[No Abstract] [Full Text] [Related]
12. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
Tefferi A; Kantarjian H
Am J Hematol; 2008 Mar; 83(3):175-7. PubMed ID: 18181199
[No Abstract] [Full Text] [Related]
13. Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
Vernon MR; Pearson L; Atallah E
J Clin Rheumatol; 2009 Aug; 15(5):267. PubMed ID: 19654496
[No Abstract] [Full Text] [Related]
14. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Hwang YY; Tse E; So JC; Wan TS; Kwong YL
Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
[No Abstract] [Full Text] [Related]
15. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
16. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
17. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
[TBL] [Abstract][Full Text] [Related]
18. Managing relapse of CML using therapeutic imatinib plasma level.
Onitilo AA; Engel JM
Clin Adv Hematol Oncol; 2009 Nov; 7(11):763-7. PubMed ID: 20075835
[No Abstract] [Full Text] [Related]
19. Imatinib and regression of type 2 diabetes.
Veneri D; Franchini M; Bonora E
N Engl J Med; 2005 Mar; 352(10):1049-50. PubMed ID: 15758023
[No Abstract] [Full Text] [Related]
20. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
